Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NC-758 (Anti amyloidotic [Aß] agent)
NC-758 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| NC-758 (Anti amyloidotic [Aß] agent) | DRUG | - |
Inclusion Criteria * Patients must be 55 years of age or older. * Males and females. Females must be of non-childbearing potential (i.e. surgically sterilized or at least one year post-menopausal). * Diagnosis of possible or probable CAA based on the Boston Criteria for Diagnosis of CAA-Related Hem...
Top 5 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 1 | PHASE3 | Milvexian |
| Grace Therapeutics, Inc. | GRCE | 1 | PHASE3 | GTX-104 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | TAK-755 |
| CervoMed Inc. | CRVO | 1 | PHASE2 | Neflamapimod |
| DiaMedica Therapeutics Inc. | DMAC | 1 | PHASE2 | DM199 |
NC-758 is an investigational small molecule developed by GSK plc for stroke in the neurology therapeutic area. It has completed a Phase 2 clinical trial in patients with lobar hemorrhage related to cerebral amyloid angiopathy. It is also known as NC-758 (Anti amyloidotic [Aß] agent).
NC-758 is being studied for stroke, specifically in patients with lobar hemorrhage related to cerebral amyloid angiopathy. The completed Phase 2 trial enrolled patients with this condition. It is not approved for any indication and remains investigational.
NC-758 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 2 trial of NC-758 in patients with lobar hemorrhage related to cerebral amyloid angiopathy.
NC-758 is in Phase 2 development. One Phase 2 trial has been completed, and there are no active trials listed. The trial was randomized and double-blind, with 30 patients enrolled. NC-758 is not approved and remains an investigational agent.
NC-758 has been evaluated in one completed Phase 2 trial, NCT00056238, titled Cerebril in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy. The trial enrolled 30 patients in the United States, ages 55 years and older, and was randomized and double-blind.
NC-758 is also known as NC-758 (Anti amyloidotic [Aß] agent). The completed Phase 2 trial was titled Cerebril in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy, indicating Cerebril is another name associated with this program.